Non-Clear Cell Renal Cell Carcinoma

Observed

→ investigated in trials for

Cabozantinibsmall molecule

13 trials (11 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

10 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sunitinibsmall molecule

6 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

4 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

4 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Atezolizumabmonoclonal antibody

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Axitinibsmall molecule

3 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fludarabinesmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Savolitinibsmall molecule

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sorafenib Tosylatesmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Everolimussmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pazopanibsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Prednisonesmall molecule

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Abirateronesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Adagrasibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Crizotinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dactinomycinother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Durvalumabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Enzalutamidesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erlotinibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erlotinib Hydrochloridesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Etoposidesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Irinotecansmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lenvatinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pegfilgrastimother

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temozolomidesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tivozanibsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Toripalimabmonoclonal antibody

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vincristinesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Chromophobe Renal Cell Carcinoma

Non-Clear Cell Renal Cell Carcinoma studied in …STUDIED_INderived10 of 62show all (up to 200)
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)	—	—	Chromophobe Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04981509Phase 2 · recruiting Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)	—	—	Papillary Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04071223Phase 2 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)	—	—	Chromophobe Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07024680completed Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)	—	—	Papillary Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03635892Phase 2 · active not recruiting A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)	—	—	Papillary Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05831891Phase 2 · active not recruiting Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)	—	—	Non-Clear Cell Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07816770Phase 2 · not yet recruiting MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas · condition mapped CURATED_BROADER · 62 trials mapped (38 active)	—	—	Non-Clear Cell Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02496208Phase 1 · active not recruiting Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)	—	—	Sarcomatoid Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05411081Phase 2 · active not recruiting Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial · condition mapped CURATED_BROADER · 62 trials mapped (38 active)	—	—	Papillary Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03793166Phase 3 · active not recruiting Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)	—	—	Sarcomatoid Renal Cell Carcinoma	1	Observed	clinicaltrials	graph →

Non-Clear Cell Renal Cell Carcinoma studied in …STUDIED_INderived10 of 62show all (up to 200)

→ studied in

NCT03866382Phase 2 · recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)

—

Observed

→ studied in

NCT04981509Phase 2 · recruiting

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)

—

Observed

Chromophobe Renal Cell Carcinoma

→ studied in

NCT04071223Phase 2 · active not recruiting

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)

—

Observed

→ studied in

NCT07024680completed

Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)

—

Observed

→ studied in

NCT03635892Phase 2 · active not recruiting

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)

—

Observed

→ studied in

NCT05831891Phase 2 · active not recruiting

Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)

—

Observed

→ studied in

NCT07816770Phase 2 · not yet recruiting

MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas · condition mapped CURATED_BROADER · 62 trials mapped (38 active)

—

Observed

Sarcomatoid Renal Cell Carcinoma

→ studied in

NCT02496208Phase 1 · active not recruiting

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)

—

Observed

→ studied in

NCT05411081Phase 2 · active not recruiting

Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial · condition mapped CURATED_BROADER · 62 trials mapped (38 active)

—

Observed

Sarcomatoid Renal Cell Carcinoma

→ studied in

NCT03793166Phase 3 · active not recruiting

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study · condition mapped ONTOLOGY_EXACT · 62 trials mapped (38 active)

—

Observed